Cartesian Therapeutics, Inc.RNACNASDAQ
LOADING
|||
Switch Symbol:
Net Income Growth Under Pressure
Trending lower, below historical average, modest growth trend.
Left:
||||
Year-over-year net income growth rate
Latest
-326.00%
↓ 346% below average
Average (39q)
-73.04%
Historical baseline
Range
High:189.70%
Low:-1873.54%
CAGR
+7.5%
Consistent expansion
| Period | Value |
|---|---|
| Q3 2025 | -326.00% |
| Q2 2025 | 189.70% |
| Q1 2025 | -72.73% |
| Q4 2024 | 57.60% |
| Q3 2024 | -274.78% |
| Q2 2024 | 124.35% |
| Q1 2024 | 68.01% |
| Q4 2023 | -1873.54% |
| Q3 2023 | 20.94% |
| Q2 2023 | 47.44% |
| Q1 2023 | -467.61% |
| Q4 2022 | 174.66% |
| Q3 2022 | -191.77% |
| Q2 2022 | -70.11% |
| Q1 2022 | 135.13% |
| Q4 2021 | 168.40% |
| Q3 2021 | -491.98% |
| Q2 2021 | 118.56% |
| Q1 2021 | -59.25% |
| Q4 2020 | -58.76% |
| Q3 2020 | 59.60% |
| Q2 2020 | -22.74% |
| Q1 2020 | -31.78% |
| Q4 2019 | -24.13% |
| Q3 2019 | 26.84% |
| Q2 2019 | -35.78% |
| Q1 2019 | 17.59% |
| Q4 2018 | 8.44% |
| Q3 2018 | 14.87% |
| Q2 2018 | -18.30% |
| Q1 2018 | 18.71% |
| Q4 2017 | -33.17% |
| Q3 2017 | 8.09% |
| Q2 2017 | -5.50% |
| Q1 2017 | -7.46% |
| Q4 2016 | -82.23% |
| Q3 2016 | -11.63% |
| Q2 2016 | 7.40% |
| Q1 2016 | -9.15% |
| Q4 2015 | -19.63% |